BMRN FY 2018 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.5B+13.5% YoY

Gross Profit

$1.2B78.9% margin

Operating Income

-$124M-8.3% margin

Net Income

-$77M-5.2% margin

EPS (Diluted)

$-0.44

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

-$124M

Stock-Based Comp.

$149M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$1.5B

Stockholders' Equity

$3.0B

Cash & Equivalents

$494M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$1.3B	+13.5%
Gross Profit	$1.2B	$1.1B	+9.7%
Operating Income	-$124M	-$15M	-740.3%
Net Income	-$77M	-$117M	+34.0%